[Immune Globulin Injection (Human), 10% Caprylate/Chromatography Purified] for Intravenous and Subcutaneous Administration
THROMBOSIS, RENAL DYSFUNCTION, and ACUTE RENAL FAILURE
- Thrombosis may occur with immune globulin products, including GAMUNEX-C. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. (see WARNINGS AND PRECAUTIONS, PATIENT INFORMATION)
- For patients at risk of thrombosis, administer GAMUNEX-C at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. (see DOSAGE AND ADMINISTRATION, WARNINGS AND PRECAUTIONS)
- Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur with immune globulin intravenous (IGIV) products in predisposed patients. Patients predisposed to renal dysfunction include those with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs.
- Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. GAMUNEX-C does not contain sucrose.
- For patients at risk of renal dysfunction or failure, administer GAMUNEX-C at the minimum concentration available and the minimum infusion rate practicable. (see WARNINGS AND PRECAUTIONS)
GAMUNEX-C is a ready-to-use sterile, non-pyrogenic solution of human immune globulin protein for intravenous and subcutaneous (PI indication only) administration. GAMUNEX-C consists of 9%–11% protein in 0.16–0.24 M glycine. Not less than 98% of the protein has the electrophoretic mobility of gamma globulin. GAMUNEX-C contains trace levels of fragments, IgA (average 0.046 mg/mL), and IgM. The distribution of IgG subclasses is similar to that found in normal serum. GAMUNEX-C doses of 1 g/kg correspond to a glycine dose of 0.15 g/kg. While toxic effects of glycine administration have been reported, the doses and rates of administration were 3–4 fold greater than those for GAMUNEX-C. In another study it was demonstrated that intravenous bolus doses of 0.44 g/kg glycine were not associated with serious adverse effects.(20) Caprylate is a saturated medium-chain (C8) fatty acid of plant origin. Medium chain fatty acids are considered to be essentially non-toxic. Human subjects receiving medium chain fatty acids parenterally have tolerated doses of 3.0 to 9.0 g/kg/day for periods of several months without adverse effects.(21) Residual caprylate concentrations in the final container are no more than 0.216 g/L (1.3 mmol/L). The measured buffer capacity is 35 mEq/L and the osmolality is 258 mOsmol/kg solvent, which is close to physiological osmolality (285-295 mOsmol/kg). The pH of GAMUNEX-C is 4.0–4.5. GAMUNEX-C contains no preservative. GAMUNEX-C is not made with natural rubber latex.
GAMUNEX-C is made from large pools of human plasma by a combination of cold ethanol fractionation, caprylate precipitation and filtration, and anion-exchange chromatography. Isotonicity is achieved by the addition of glycine. GAMUNEX-C is incubated in the final container (at the low pH of 4.0–4.3). The product is intended for intravenous administration and may be administered subcutaneously in treatment of PI.
The capacity of the manufacturing process to remove and/or inactivate enveloped and non-enveloped viruses has been validated by laboratory spiking studies on a scaled down process model, using the following enveloped and non-enveloped viruses: human immunodeficiency virus, type I (HIV-1) as the relevant virus for HIV-1 and HIV–2; bovine viral diarrhea virus (BVDV) as a model for hepatitis C virus; pseudorabies virus (PRV) as a model for large enveloped DNA viruses (e.g., herpes viruses); Reovirus type 3 (Reo) as a model for non-enveloped viruses and for its resistance to physical and chemical inactivation; hepatitis A virus (HAV) as relevant non-enveloped virus, and porcine parvovirus (PPV) as a model for human parvovirus B19.(22)
Overall virus reduction was calculated only from steps that were mechanistically independent from each other and truly additive. In addition, each step was verified to provide robust virus reduction across the production range for key operating parameters.
Table 12: Log10 Virus
|Process Step||Log10 Virus Reduction|
|Enveloped Viruses||Non-enveloped Viruses|
|Caprylate Precipitation/Depth Filtration||C/I*||C/I||2.7||≥ 3.5||≥ 3.6||4.0|
|Caprylate Incubation||≥ 4.5||≥ 4.6||≥ 4.5||NA†||NA||NA|
|Depth Filtration*||CAP§||CAP||CAP||≥ 4.3||≥ 2.0||3.3|
|Column Chromatography||≥ 3.0||≥ 3.3||4.0||≥ 4.0||≥ 1.4||4.2|
|Low pH Incubation||≥ 6.5||≥ 4.3||≥ 5.1||NA||NA||NA|
|Global Reduction||≥ 14.0||≥ 12.2||≥ 16.3||≥ 7.5||≥ 5.0||8.2|
|* C/I - Interference by caprylate precluded determination
of virus reduction for this step. Although removal of viruses is likely to
occur at the caprylate precipitation/depth filtration step, BVDV is the only
enveloped virus for which reduction is claimed. The presence of caprylate
prevents detection of other, less resistant enveloped viruses and therefore
their removal cannot be assessed.
† NA - Not Applicable: This step has no effect on non-enveloped viruses.
‡ Some mechanistic overlap occurs between depth filtration and other steps. Therefore, Grifols Therapeutics Inc. has chosen to exclude this step from the global virus reduction calculations.
§ CAP - The presence of caprylate in the process at this step prevents detection of enveloped viruses, and their removal cannot be assessed.
Additionally, the manufacturing process was investigated for its capacity to decrease the infectivity of an experimental agent of transmissible spongiform encephalopathy (TSE), considered as a model for the vCJD and CJD agents.(22)
Several of the individual production steps in the GAMUNEX-C manufacturing process have been shown to decrease TSE infectivity of that experimental model agent. TSE reduction steps include two depth filtrations (in sequence, a total of ≥ 6.6 log10). These studies provide reasonable assurance that low levels of CJD/vCJD agent infectivity, if present in the starting material, would be removed.
20. Tai VM, Mitchell EJ, Lee-Brotherton V,et al. Safety evaluation of intravenous glycine in formulation development. J Pharm Pharmaceut Sci 2000;3:198.
21. Traul KA, Driedger A, Ingle D, et al. Review of the toxicologic properties of medium-chain triglycerides. Food Chem Toxicol 2000;38(1):79-98.
22. Barnette D, Roth NJ, Hotta J, et al. Pathogen safety profile of a 10% IgG preparation manufactured using a depth filtration-modified process. Biologicals 2012;40:247-53.
Last reviewed on RxList: 4/5/2016
This monograph has been modified to include the generic and brand name in many instances.
Additional Gamunex-C Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.